Neuronetics Inc expected to post a loss of 12 cents a share - Earnings Preview
Neuronetics Inc expected to post a loss of 12 cents a share - Earnings Preview
Neuronetics Inc STIM.OQ STIM.O is expected to show a rise in quarterly revenue when it reports results on August 11 for the period ending June 30 2026
The Malvern Pennsylvania-based company is expected to report a 5.4% increase in revenue to $40.175 million from $38.11 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.The company's guidance on May 5 2026, for the period ended June 30, was for revenue between $39.63 million and $40.39 million.
LSEG's mean analyst estimate for Neuronetics Inc is for a loss of 12 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Neuronetics Inc is $4.00, about 77.8% above its last closing price of $2.25
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.17 | -0.17 | -0.15 | Beat | 13.5 |
Dec. 31 2026 | -0.11 | -0.10 | Beat | 6.3 | |
Sep. 30 2025 | -0.12 | -0.13 | -0.13 | Met | -2.6 |
Jun. 30 2025 | -0.07 | -0.08 | -0.15 | Missed | -95.6 |
Mar. 31 2025 | -0.13 | -0.12 | -0.21 | Missed | -68 |
Dec. 31 2024 | -0.25 | -0.21 | -0.33 | Missed | -57.1 |
Sep. 30 2024 | -0.23 | -0.23 | -0.44 | Missed | -91.3 |
Jun. 30 2024 | -0.27 | -0.27 | -0.33 | Missed | -22.2 |
This summary was machine generated August 7 at 16:27 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Neuronetics
See all newsNeuronetics Inc reports results for the quarter ended June 30 - Earnings Summary
Neuronetics Q2 revenue beats estimates on Greenbrook clinic strength
Neuronetics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Neuronetics Appoints Nir Naor Chief Financial Officer Announces Additional Management Changes